

Flemming Bendtsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6424196/publications.pdf>

Version: 2024-02-01

108
papers

5,754
citations

109137

35
h-index

79541

73
g-index

110
all docs

110
docs citations

110
times ranked

7719
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2015, 149, 389-397.e10.	0.6	2,200
2	Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2016, 64, 574-582.	1.8	196
3	Mortality, Cancer, and Comorbidities Associated With Chronic Pancreatitis: A Danish Nationwide Matched-Cohort Study. <i>Gastroenterology</i> , 2014, 146, 989-994.e1.	0.6	177
4	The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1407-1415.	0.6	159
5	Disease Course and Surgery Rates in Inflammatory Bowel Disease: A Population-Based, 7-Year Follow-Up Study in the Era of Immunomodulating Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 705-714.	0.2	150
6	The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. <i>Liver International</i> , 2018, 38, 570-580.	1.9	136
7	Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. <i>Gastroenterology</i> , 1995, 109, 1917-1925.	0.6	130
8	Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. <i>Liver</i> , 2000, 20, 51-59.	0.1	120
9	Acute non-selective β_2 -adrenergic blockade reduces prolonged frequency-adjusted QTc interval (QTc) in patients with cirrhosis. <i>Journal of Hepatology</i> , 2004, 40, 239-246.	1.8	116
10	Lactate metabolism in chronic liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2013, 73, 293-299.	0.6	110
11	Increased circulating leptin in alcoholic cirrhosis: Relation to release and disposal. <i>Hepatology</i> , 1999, 29, 1818-1824.	3.6	92
12	Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, β_2 -adrenergic blockade and atrial natriuretic factor. <i>Hepatology</i> , 1992, 16, 1163-1170.	3.6	76
13	Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. <i>World Journal of Gastroenterology</i> , 2014, 20, 15499.	1.4	62
14	The Risk of Fractures Among Patients With Cirrhosis or Chronic Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 320-326.	2.4	61
15	Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. <i>Hepatology</i> , 2017, 65, 592-603.	3.6	60
16	Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G970-G979.	1.6	59
17	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E505-E514.	1.8	56
18	Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G584-G594.	1.6	55

#	ARTICLE	IF	CITATIONS
19	Management of cirrhotic ascites. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 124-137.	1.1	55
20	Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011: A Danish population-based cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1675-1683.	0.6	54
21	Circulating atrial natriuretic peptide (ANP) and central blood volume (CBV) in cirrhosis. <i>Liver</i> , 1986, 6, 361-368.	0.1	51
22	Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 307-314.	1.4	51
23	Carvedilol or propranolol in portal hypertension? A randomized comparison. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 467-474.	0.6	47
24	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	6.1	47
25	Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	1.9	46
26	Diurnal variation and dispersion in QT interval in cirrhosis: Relation to haemodynamic changes. <i>Journal of Hepatology</i> , 2007, 47, 373-380.	1.8	45
27	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 211-222.	2.0	45
28	Bile acids and cardiovascular function in cirrhosis. <i>Liver International</i> , 2017, 37, 1420-1430.	1.9	44
29	Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G275-G286.	1.6	44
30	A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1227-1236.	0.9	44
31	Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials. <i>Journal of Hepatology</i> , 2014, 61, 252-259.	1.8	43
32	Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 584-592.	0.6	43
33	Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies: A Danish population-based cohort study. <i>Journal of Autoimmunity</i> , 2021, 118, 102613.	3.0	41
34	Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. <i>Liver International</i> , 2014, 34, 1153-1163.	1.9	40
35	Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow-up in a Danish Population-based Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 53-63.	0.6	39
36	Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 451-458.	0.6	37

#	ARTICLE	IF	CITATIONS
37	Cirrhotic Multiorgan Syndrome. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3209-3225.	1.1	35
38	Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1200-1204.	0.6	34
39	An update on cirrhotic cardiomyopathy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 497-505.	1.4	33
40	Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome. <i>Liver International</i> , 2018, 38, 1614-1623.	1.9	30
41	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. <i>PLoS ONE</i> , 2014, 9, e108544.	1.1	29
42	Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. <i>The Cochrane Library</i> , 2018, 2018, CD011510.	1.5	29
43	Effect of oral propranolol administration on azygos, renal and hepatic uptake and output of catecholamines in cirrhosis. <i>Hepatology</i> , 1991, 14, 237-243.	3.6	28
44	Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. <i>Hepatology</i> , 2004, 40, 811-819.	3.6	28
45	Assessment of response to beta-blockers by expression of β^2 Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. <i>Journal of Hepatology</i> , 2016, 64, 1265-1273.	1.8	27
46	Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial. <i>Hepatology</i> , 2001, 34, 471-477.	3.6	26
47	Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. <i>Liver International</i> , 2019, 39, 885-893.	1.9	26
48	Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 560-569.	0.6	26
49	Splanchnic and renal extraction of circulating type III procollagen aminoterminal propeptide in patients with normal liver function and in patients with alcoholic cirrhosis. <i>Hepatology</i> , 1990, 11, 957-963.	3.6	25
50	Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, 1353-1359.	0.4	24
51	Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1093-1099.	1.4	22
52	Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1070-1080.	1.9	22
53	Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. <i>Journal of Clinical Medicine</i> , 2021, 10, 3783.	1.0	21
54	Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: A randomised study. <i>Digestive and Liver Disease</i> , 2014, 46, 251-256.	0.4	19

#	ARTICLE	IF	CITATIONS
55	Cardiac dysfunction in cirrhosis: a 2-yr longitudinal follow-up study using advanced cardiac imaging. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G253-G263.	1.6	19
56	Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort. <i>United European Gastroenterology Journal</i> , 2019, 7, 942-954.	1.6	17
57	Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 1353-1362.	1.9	17
58	Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 5362-5374.	1.4	17
59	Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis. <i>Digestive and Liver Disease</i> , 2022, 54, 1168-1178.	0.4	17
60	Serum levels of short-chain fatty acids in cirrhosis and hepatic coma. <i>Hepatology</i> , 1991, 14, 1040-1045.	3.6	16
61	Hepatic venous oxygen content in alcoholic cirrhosis and non-cirrhotic alcoholic liver disease. <i>Liver</i> , 1987, 7, 176-181.	0.1	16
62	NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8+ T cell migration. <i>Experimental and Molecular Pathology</i> , 2017, 103, 56-70.	0.9	16
63	Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 927-939.	0.9	16
64	Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1153-1161.	1.4	15
65	Incidence, Risk Factors and Evaluation of Osteoporosis in Patients With Inflammatory Bowel Disease: A Danish Population-Based Inception Cohort With 10 Years of Follow-Up. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 904-914.	0.6	15
66	Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis. <i>Liver International</i> , 2021, 41, 2149-2158.	1.9	15
67	Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study. <i>PLoS ONE</i> , 2014, 9, e109179.	1.1	15
68	Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. <i>Nature Communications</i> , 2022, 13, .	5.8	14
69	Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 392-397.	0.8	13
70	Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1040-1048.	0.6	12
71	Bacteraemia after injection sclerotherapy of oesophageal varices. <i>Liver</i> , 1988, 8, 167-171.	0.1	11
72	Reply. <i>Gastroenterology</i> , 2014, 147, 542.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease – a real-world two-center cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e709-e718.	0.8	11
74	Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G313-G321.	1.6	10
75	Left atrial volume changes assessed by real time 3-dimensional echocardiography in relation to liver function and prognosis in patients with cirrhosis. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 2121-2127.	0.7	10
76	Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir. <i>Clinical Infectious Diseases</i> , 2021, 73, e811-e814.	2.9	10
77	Assessment of central blood volume in cirrhosis by radionuclide angiography: What does it really mean?. <i>Hepatology</i> , 1994, 20, 1652-1656.	3.6	9
78	The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. <i>Liver</i> , 2001, 21, 350-356.	0.1	9
79	Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1355-1362.	1.1	8
80	Acetaminophen toxicity induces mitochondrial complex I inhibition in human liver tissue. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 86-91.	1.2	8
81	Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2020, 10, e035284.	0.8	8
82	Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 404-408.	0.4	6
83	No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. <i>PLoS ONE</i> , 2018, 13, e0203200.	1.1	6
84	Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. <i>Journal of Infectious Diseases</i> , 2020, 224, 443-452.	1.9	6
85	Pathophysiological-based treatments of complications of cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 383-394.	0.6	6
86	Long-Term, Clinical Follow-Up in Fatty Liver Patients. <i>Digestive Diseases</i> , 2010, 28, 709-714.	0.8	5
87	Presence of alcoholic steatohepatitis, but no selective histological feature, indicates an increased risk of cirrhosis and premature death. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1367-1374.	0.6	5
88	Neutrophil gelatinase-associated lipocalin and cystatin C in cirrhosis and portal hypertension: Relations to organ extraction and dysfunction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 473-481.	1.4	5
89	Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 200-205.	0.6	5
90	Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2022, , .	0.9	5

#	ARTICLE	IF	CITATIONS
91	Effects on Plasma Angiotensinâ€Converting Enzyme Activity and Circulating Renin of Lisinopril and Enalapril Alone and in Combination with Propranolol in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 1999, 84, 110-114.	0.0	4
92	Treatment of ascites and spontaneous bacterial peritonitis - part I. Danish Medical Journal, 2012, 59, C4371.	0.5	4
93	Cardiovascular complications of NAFLDâ€”they do matter. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 434-436.	8.2	3
94	The royal free hospital cirrhosis glomerular filtration rate: Validation in a danish cohort. Hepatology, 2017, 66, 1360-1361.	3.6	3
95	Aquaporinâ€2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1087-1093.	1.4	3
96	A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019. Scandinavian Journal of Gastroenterology, 2021, 56, 453-457.	0.6	3
97	Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, Î²-adrenergic blockade and atrial natriuretic factor. Hepatology, 1992, 16, 1163-1170.	3.6	3
98	Pharmacological effects are model specific in animal models of portal hypertension. Hepatology International, 2008, 2, 397-398.	1.9	2
99	Gammaâ€variate plasma clearance versus urinary plasma clearance of ⁵¹ Crâ€EDTA in patients with cirrhosis with and without fluid retention. Clinical Physiology and Functional Imaging, 2017, 37, 588-595.	0.5	2
100	Poor Concordance Between Liver Stiffness and Noninvasive Fibrosis Scores in HIV Infection Without Viral Hepatitis. Clinical Gastroenterology and Hepatology, 2020, 18, 3049-3050.	2.4	2
101	Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohnâ€™s disease. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110048.	1.4	2
102	Gastric Emptying Is Not Delayed and Does Not Correlate With Attenuated Postprandial Blood Flow Increase in Medicated Patients With Early Parkinson's Disease. Frontiers in Neurology, 2022, 13, 828069.	1.1	2
103	Postprandial Increase in Mesenteric Blood Flow is Attenuated in Parkinsonâ€™s Disease: A Dynamic PC-MRI Study. Journal of Parkinson's Disease, 2021, 11, 545-557.	1.5	1
104	Outcomes of COVID-19 among Patients with Chronic Liver Disease: A Danish Prospective, Population-Based Cohort Study. GastroHep, 2022, 2022, 1-10.	0.3	1
105	Pitfalls in the assessment of intrapulmonary shunt using lung perfusion scintigraphy in patients with cirrhosis: authors' reply. Liver International, 2011, 31, 139-140.	1.9	0
106	Red blood cell sodium transport in patients with cirrhosis. Clinical Physiology and Functional Imaging, 2016, 36, 359-367.	0.5	0
107	Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. Current Hepatology Reports, 2017, 16, 250-257.	0.4	0
108	Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 692-699.	1.4	0